After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

SAN FRANCISCO, December 09, 2024--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage ...

Should you be buying the dip? Let's find out. The post Why did CSL shares crash 39% in 2025? appeared first on The Motley ...

Organ transplants take a physical, emotional and mental toll. So CSL Behring and Lyfebulb created the first online community for transplant patients, family and friends, and living organ donors.

When Biogen recently announced its top dog for manufacturing and supply chain operations was leaving to become chief operating officer for another company, the question was, which one? The question ...

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

The FDA has accepted CSL Behring’s priority review application for a hemophilia B gene therapy, potentially fast-tracking the drug after a bumpy ride that included a clinical hold—and later, a lift.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. At BIO 2019, happening June 3 to 6 at the Convention Center ...

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global ...

The therapy was approved to treat a rare condition that afflicts about 40,000 people in the United States. The Food and Drug Administration has approved King of Prussia-based CSL Behring’s autoimmune ...